Trelegy Ellipta Reduces COPD Exacerbations in Landmark Trial

A landmark trial comparing triple therapy fluticasone furoate/umeclidinium/vilaterol (FF/UMEC/VI [Trelegy Ellipta]) versus FF/VI (Relvar; Breo) or FF/UMEC (Anoro) found the former is markedly better in reducing annual rate of on-treatment of moderate/severe exacerbations in patients with chronic obstructive pulmonary disease (COPD).

A landmark trial comparing triple therapy fluticasone furoate/umeclidinium/vilaterol (FF/UMEC/VI [Trelegy Ellipta]) versus FF/VI (Relvar; Breo) or FF/UMEC (Anoro) found the former is markedly better in reducing annual rate of on-treatment of moderate/severe exacerbations in patients with chronic obstructive pulmonary disease (COPD).

The 10,335-patient Informing the Pathway of COPD Treatment (IMPACT) study compared 52 weeks of once-daily set dose of FF/UMEC/VI (100mg/62.5mg/25mg) to fixed doses of the double-therapy options. Each regimen was administered via a single Ellipta inhaler, and results were measured for a primary outcome of annual rate of moderate or severe COPD exacerbations during treatment.

Enrolled patients were aged 40 years or older, with symptomatic COPD. They also either had a forced expiratory volume in 1 second (FEV1) of less than 50% normally predicted value plus a history of at least one moderate to severe exacerbation in the past year, or an FEV1 of 50-80% of normally predicted value plus at least 2 exacerbations in the past year.

Click to continue reading on MD Magazine.